FeesSafety
Pluang+

Three ultra-high-yield BDC lenders offer 13%+ payouts, but only Blue Owl's dividend looks sustainable.

Market News
24 Oct 2026
24/7 Wall Street
View Source
Bearish
Three ultra-high-yield BDC lenders offer 13%+ payouts, but only Blue Owl's dividend looks sustainable.

Three business development companies (BDCs) offer yields above 13%, but their payout sustainability varies. FS KKR Capital yields 21.3% but shows red flags like negative earnings and a shrinking loan book, making its dividend risky. Blue Owl Capital cut its dividend to match earnings, yielding 14.4%, with strong coverage and an investment-grade rating, making it the safest choice. Blackstone Secured Lending yields 13.1% with a steady payout and high-quality loans but has thin coverage that could pressure future dividends if rates fall further.

The three ultra-high-yield lenders story provides context for financial stocks on Pluang. For readers following this sector, here is Pluang's market snapshot as of Oct 24, 2026 18:51 WIB: Out of 142 priced Financials-sector US stocks, 21 rose and 119 fell. Notable movers include GLXY at USD 14.68 with a -3.99% change, CBOE at USD 340.42 with a +3.88% change and a 42% Sell / 58% Buy order split, and UNM at USD 90.28 with a -3.70% change. Typical hold times range from 5 to 9 days on Pluang.

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
2 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
2 hours ago
New Proof of Human feature links Alien ID to Solana wallets for real user verification.

New Proof of Human feature links Alien ID to Solana wallets for real user verification.

A new Proof of Human feature allows users to link an Alien ID to any Solana wallet, verifying that a real person controls the wallet. This initiative aims to enhance trust and security in blockchain transactions by confirming human identity behind wa...

Protocol Fundamentals
Neutral
4 hours ago
Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...

Market News
Bullish
4 hours ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App